| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 73 | 2025 | 767 | 17.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 71 | 2025 | 1231 | 10.790 |
Why?
|
| Endocrinology | 16 | 2022 | 50 | 10.660 |
Why?
|
| Hypoglycemic Agents | 42 | 2025 | 379 | 5.970 |
Why?
|
| Blood Glucose | 48 | 2024 | 868 | 4.930 |
Why?
|
| Diabetes Mellitus, Type 1 | 22 | 2025 | 589 | 3.980 |
Why?
|
| Aging | 24 | 2025 | 727 | 3.580 |
Why?
|
| Medicaid | 12 | 2024 | 259 | 3.580 |
Why?
|
| Blood Glucose Self-Monitoring | 13 | 2022 | 62 | 2.810 |
Why?
|
| Reference Standards | 16 | 2022 | 146 | 2.740 |
Why?
|
| Standard of Care | 16 | 2022 | 70 | 2.720 |
Why?
|
| Diabetes Complications | 20 | 2024 | 170 | 2.600 |
Why?
|
| Community Health Centers | 14 | 2023 | 119 | 2.460 |
Why?
|
| United States | 81 | 2026 | 7645 | 2.430 |
Why?
|
| Hypoglycemia | 19 | 2024 | 113 | 2.420 |
Why?
|
| Aged | 115 | 2025 | 20469 | 2.410 |
Why?
|
| Humans | 235 | 2026 | 93615 | 2.380 |
Why?
|
| Cost-Benefit Analysis | 25 | 2025 | 494 | 2.190 |
Why?
|
| Societies, Medical | 16 | 2022 | 623 | 2.150 |
Why?
|
| Insulin | 17 | 2024 | 1185 | 1.900 |
Why?
|
| Healthcare Disparities | 13 | 2016 | 496 | 1.840 |
Why?
|
| Cardiovascular Diseases | 14 | 2025 | 755 | 1.710 |
Why?
|
| Male | 132 | 2025 | 44578 | 1.690 |
Why?
|
| Female | 136 | 2025 | 48779 | 1.680 |
Why?
|
| Middle Aged | 99 | 2025 | 27621 | 1.620 |
Why?
|
| Quality of Life | 21 | 2023 | 1783 | 1.480 |
Why?
|
| Health Status Disparities | 6 | 2024 | 219 | 1.470 |
Why?
|
| Primary Health Care | 13 | 2022 | 379 | 1.420 |
Why?
|
| Quality-Adjusted Life Years | 15 | 2025 | 157 | 1.300 |
Why?
|
| Aged, 80 and over | 39 | 2025 | 7073 | 1.220 |
Why?
|
| Patient Protection and Affordable Care Act | 5 | 2022 | 64 | 1.140 |
Why?
|
| Adult | 73 | 2025 | 27955 | 1.110 |
Why?
|
| Social Support | 5 | 2024 | 233 | 1.100 |
Why?
|
| Dementia | 9 | 2025 | 214 | 1.100 |
Why?
|
| Longitudinal Studies | 16 | 2025 | 1165 | 1.080 |
Why?
|
| Ambulatory Care Facilities | 6 | 2022 | 117 | 1.060 |
Why?
|
| Insurance, Health | 5 | 2016 | 180 | 1.060 |
Why?
|
| Insurance Coverage | 6 | 2019 | 144 | 1.050 |
Why?
|
| Delivery of Health Care | 8 | 2026 | 453 | 1.040 |
Why?
|
| Cross-Sectional Studies | 23 | 2024 | 1866 | 1.030 |
Why?
|
| Comorbidity | 17 | 2025 | 1007 | 0.980 |
Why?
|
| Health Services for the Aged | 3 | 2015 | 32 | 0.960 |
Why?
|
| Quality Improvement | 7 | 2022 | 485 | 0.950 |
Why?
|
| Health Expenditures | 4 | 2016 | 102 | 0.940 |
Why?
|
| Obesity | 7 | 2025 | 1019 | 0.940 |
Why?
|
| Minority Groups | 4 | 2024 | 149 | 0.930 |
Why?
|
| Health Status | 10 | 2023 | 377 | 0.930 |
Why?
|
| Risk Factors | 29 | 2025 | 5912 | 0.910 |
Why?
|
| Community-Institutional Relations | 1 | 2025 | 31 | 0.890 |
Why?
|
| Community-Based Participatory Research | 1 | 2025 | 38 | 0.890 |
Why?
|
| Risk Assessment | 14 | 2025 | 2444 | 0.880 |
Why?
|
| Decision Support Techniques | 4 | 2016 | 185 | 0.880 |
Why?
|
| Appointments and Schedules | 2 | 2019 | 58 | 0.850 |
Why?
|
| Prediabetic State | 2 | 2024 | 42 | 0.850 |
Why?
|
| Health Facility Closure | 1 | 2024 | 7 | 0.830 |
Why?
|
| Propensity Score | 2 | 2024 | 178 | 0.820 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 108 | 0.820 |
Why?
|
| Precision Medicine | 4 | 2019 | 456 | 0.800 |
Why?
|
| Quality of Health Care | 9 | 2026 | 383 | 0.800 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2025 | 256 | 0.790 |
Why?
|
| Chronic Disease | 5 | 2016 | 962 | 0.790 |
Why?
|
| Hypertension | 6 | 2024 | 758 | 0.780 |
Why?
|
| Insulin Infusion Systems | 4 | 2023 | 44 | 0.780 |
Why?
|
| Health Care Costs | 7 | 2024 | 252 | 0.770 |
Why?
|
| Frailty | 2 | 2021 | 94 | 0.760 |
Why?
|
| Eligibility Determination | 3 | 2022 | 39 | 0.760 |
Why?
|
| Adolescent | 29 | 2024 | 9610 | 0.760 |
Why?
|
| Safety-net Providers | 5 | 2019 | 45 | 0.750 |
Why?
|
| Patient-Centered Care | 10 | 2022 | 224 | 0.740 |
Why?
|
| Patient Satisfaction | 7 | 2012 | 485 | 0.710 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2023 | 293 | 0.690 |
Why?
|
| Health Services Needs and Demand | 3 | 2024 | 110 | 0.670 |
Why?
|
| Retinal Diseases | 1 | 2022 | 84 | 0.670 |
Why?
|
| Hospitalization | 7 | 2020 | 938 | 0.670 |
Why?
|
| Genetic Testing | 3 | 2019 | 565 | 0.670 |
Why?
|
| Young Adult | 26 | 2025 | 6938 | 0.660 |
Why?
|
| Cohort Studies | 18 | 2024 | 3061 | 0.650 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2019 | 34 | 0.640 |
Why?
|
| Children's Health Insurance Program | 1 | 2020 | 2 | 0.630 |
Why?
|
| Public Sector | 1 | 2020 | 13 | 0.620 |
Why?
|
| Private Sector | 1 | 2020 | 20 | 0.620 |
Why?
|
| Electronic Health Records | 9 | 2024 | 374 | 0.620 |
Why?
|
| Financing, Personal | 2 | 2016 | 21 | 0.610 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2017 | 64 | 0.610 |
Why?
|
| Logistic Models | 10 | 2024 | 1246 | 0.600 |
Why?
|
| Child | 20 | 2024 | 7359 | 0.600 |
Why?
|
| Comparative Effectiveness Research | 2 | 2023 | 57 | 0.600 |
Why?
|
| Polypharmacy | 3 | 2016 | 21 | 0.600 |
Why?
|
| Osteoporotic Fractures | 3 | 2025 | 53 | 0.590 |
Why?
|
| Life Expectancy | 7 | 2023 | 91 | 0.580 |
Why?
|
| Physicians | 4 | 2019 | 683 | 0.570 |
Why?
|
| Residence Characteristics | 3 | 2017 | 213 | 0.560 |
Why?
|
| California | 12 | 2025 | 158 | 0.550 |
Why?
|
| Odds Ratio | 7 | 2015 | 713 | 0.540 |
Why?
|
| Caregivers | 3 | 2024 | 180 | 0.540 |
Why?
|
| Chicago | 10 | 2025 | 1464 | 0.520 |
Why?
|
| Quality Assurance, Health Care | 6 | 2012 | 225 | 0.510 |
Why?
|
| Frail Elderly | 4 | 2021 | 92 | 0.510 |
Why?
|
| Geriatric Assessment | 4 | 2021 | 188 | 0.500 |
Why?
|
| Health Policy | 3 | 2026 | 207 | 0.500 |
Why?
|
| Hypercholesterolemia | 2 | 2017 | 160 | 0.500 |
Why?
|
| Public Health | 2 | 2012 | 154 | 0.490 |
Why?
|
| Drug Costs | 5 | 2025 | 66 | 0.490 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 3835 | 0.490 |
Why?
|
| Child Health Services | 1 | 2016 | 47 | 0.490 |
Why?
|
| Blood Pressure | 8 | 2019 | 896 | 0.480 |
Why?
|
| Deprescriptions | 3 | 2025 | 10 | 0.480 |
Why?
|
| Physicians, Primary Care | 2 | 2015 | 110 | 0.480 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 125 | 0.480 |
Why?
|
| Disease Progression | 6 | 2024 | 1531 | 0.470 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 394 | 0.470 |
Why?
|
| Telemedicine | 1 | 2019 | 225 | 0.470 |
Why?
|
| Home Care Services | 1 | 2017 | 77 | 0.460 |
Why?
|
| Drug Labeling | 1 | 2015 | 41 | 0.460 |
Why?
|
| Physicians, Family | 2 | 2008 | 35 | 0.460 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 77 | 0.450 |
Why?
|
| Medicare | 7 | 2025 | 455 | 0.440 |
Why?
|
| Diabetic Foot | 4 | 2019 | 16 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 624 | 0.440 |
Why?
|
| Forecasting | 3 | 2013 | 294 | 0.440 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 142 | 0.440 |
Why?
|
| Body Mass Index | 7 | 2023 | 812 | 0.440 |
Why?
|
| Monitoring, Ambulatory | 5 | 2018 | 32 | 0.430 |
Why?
|
| Medically Underserved Area | 2 | 2022 | 26 | 0.430 |
Why?
|
| Surveys and Questionnaires | 13 | 2025 | 2806 | 0.420 |
Why?
|
| Socioeconomic Factors | 9 | 2017 | 629 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2023 | 920 | 0.410 |
Why?
|
| Retrospective Studies | 18 | 2023 | 10186 | 0.410 |
Why?
|
| Federal Government | 2 | 2014 | 28 | 0.410 |
Why?
|
| Preventive Health Services | 1 | 2014 | 38 | 0.410 |
Why?
|
| Health Care Reform | 2 | 2015 | 83 | 0.400 |
Why?
|
| Age Factors | 10 | 2021 | 1907 | 0.400 |
Why?
|
| Office Visits | 2 | 2017 | 47 | 0.400 |
Why?
|
| Costs and Cost Analysis | 4 | 2023 | 154 | 0.390 |
Why?
|
| Decision Making | 2 | 2016 | 674 | 0.390 |
Why?
|
| Models, Theoretical | 2 | 2013 | 494 | 0.380 |
Why?
|
| Heart Transplantation | 4 | 2020 | 813 | 0.380 |
Why?
|
| Referral and Consultation | 3 | 2021 | 376 | 0.380 |
Why?
|
| Gastrointestinal Agents | 2 | 2021 | 181 | 0.370 |
Why?
|
| Prevalence | 8 | 2025 | 1322 | 0.370 |
Why?
|
| Cooperative Behavior | 3 | 2025 | 192 | 0.370 |
Why?
|
| Registries | 6 | 2020 | 996 | 0.370 |
Why?
|
| Disease Management | 5 | 2016 | 359 | 0.360 |
Why?
|
| Language | 1 | 2014 | 162 | 0.360 |
Why?
|
| Insurance Claim Review | 2 | 2024 | 47 | 0.360 |
Why?
|
| Pediatrics | 1 | 2016 | 386 | 0.360 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 385 | 0.360 |
Why?
|
| Health Services Research | 6 | 2017 | 143 | 0.360 |
Why?
|
| Program Evaluation | 3 | 2014 | 315 | 0.360 |
Why?
|
| Models, Biological | 1 | 2019 | 1768 | 0.360 |
Why?
|
| Incidence | 10 | 2017 | 1702 | 0.350 |
Why?
|
| Bariatric Surgery | 2 | 2014 | 208 | 0.350 |
Why?
|
| Sulfonylurea Compounds | 3 | 2024 | 72 | 0.350 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 217 | 0.340 |
Why?
|
| Depression | 6 | 2013 | 544 | 0.340 |
Why?
|
| Total Quality Management | 2 | 2008 | 32 | 0.330 |
Why?
|
| Health Services Accessibility | 7 | 2022 | 490 | 0.330 |
Why?
|
| Biomarkers | 6 | 2019 | 1912 | 0.330 |
Why?
|
| Physician-Patient Relations | 4 | 2016 | 577 | 0.320 |
Why?
|
| Program Development | 2 | 2007 | 131 | 0.310 |
Why?
|
| Patient Preference | 2 | 2025 | 125 | 0.310 |
Why?
|
| Health Surveys | 5 | 2021 | 245 | 0.310 |
Why?
|
| Trust | 2 | 2025 | 97 | 0.300 |
Why?
|
| Data Accuracy | 2 | 2023 | 32 | 0.300 |
Why?
|
| Pancreatic Cyst | 1 | 2009 | 29 | 0.300 |
Why?
|
| Databases, Factual | 3 | 2019 | 1006 | 0.300 |
Why?
|
| Population Density | 1 | 2009 | 70 | 0.300 |
Why?
|
| Accidental Falls | 1 | 2009 | 48 | 0.300 |
Why?
|
| Health Facility Administrators | 2 | 2010 | 15 | 0.300 |
Why?
|
| Metformin | 3 | 2024 | 125 | 0.290 |
Why?
|
| Self Care | 5 | 2013 | 167 | 0.290 |
Why?
|
| Markov Chains | 4 | 2021 | 136 | 0.290 |
Why?
|
| Cost of Illness | 1 | 2009 | 159 | 0.290 |
Why?
|
| Professional-Patient Relations | 3 | 2014 | 48 | 0.280 |
Why?
|
| Burnout, Professional | 4 | 2019 | 113 | 0.280 |
Why?
|
| Drug Therapy | 1 | 2008 | 68 | 0.280 |
Why?
|
| Hospitals | 2 | 2022 | 330 | 0.270 |
Why?
|
| Mass Screening | 4 | 2019 | 711 | 0.270 |
Why?
|
| Diabetic Retinopathy | 3 | 2016 | 82 | 0.270 |
Why?
|
| Rifamycins | 1 | 2007 | 7 | 0.270 |
Why?
|
| Attitude of Health Personnel | 7 | 2019 | 660 | 0.270 |
Why?
|
| Emergency Service, Hospital | 3 | 2018 | 582 | 0.270 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 1715 | 0.270 |
Why?
|
| Quality Indicators, Health Care | 3 | 2020 | 154 | 0.260 |
Why?
|
| Lactulose | 1 | 2007 | 22 | 0.260 |
Why?
|
| Hepatic Encephalopathy | 1 | 2007 | 35 | 0.260 |
Why?
|
| Genomics | 1 | 2013 | 848 | 0.260 |
Why?
|
| Financial Management | 1 | 2007 | 21 | 0.260 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 381 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 7 | 2025 | 1056 | 0.260 |
Why?
|
| Laboratories, Hospital | 1 | 2007 | 11 | 0.260 |
Why?
|
| Computer Simulation | 3 | 2024 | 1119 | 0.260 |
Why?
|
| Liver Failure | 1 | 2007 | 69 | 0.260 |
Why?
|
| Preoperative Care | 1 | 2009 | 407 | 0.260 |
Why?
|
| Morale | 4 | 2019 | 16 | 0.260 |
Why?
|
| Prescription Drugs | 2 | 2020 | 38 | 0.260 |
Why?
|
| Treatment Outcome | 11 | 2019 | 9108 | 0.250 |
Why?
|
| Health Plan Implementation | 1 | 2007 | 63 | 0.250 |
Why?
|
| Infant | 4 | 2021 | 3222 | 0.250 |
Why?
|
| Patient Care Management | 2 | 2011 | 29 | 0.250 |
Why?
|
| Monte Carlo Method | 3 | 2017 | 192 | 0.250 |
Why?
|
| Hip Fractures | 2 | 2025 | 51 | 0.250 |
Why?
|
| Medication Adherence | 2 | 2019 | 122 | 0.250 |
Why?
|
| Time Factors | 8 | 2019 | 5406 | 0.240 |
Why?
|
| Bone Density | 2 | 2025 | 237 | 0.240 |
Why?
|
| Job Satisfaction | 3 | 2019 | 80 | 0.240 |
Why?
|
| Educational Status | 2 | 2025 | 197 | 0.240 |
Why?
|
| Attitude to Health | 3 | 2016 | 217 | 0.230 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 291 | 0.230 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 262 | 0.230 |
Why?
|
| Goals | 2 | 2006 | 67 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 836 | 0.220 |
Why?
|
| Medicare Part D | 1 | 2025 | 12 | 0.220 |
Why?
|
| Glucagon-Like Peptides | 1 | 2025 | 16 | 0.220 |
Why?
|
| Anti-Obesity Agents | 1 | 2025 | 16 | 0.220 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 30 | 0.220 |
Why?
|
| Colorado | 3 | 2021 | 39 | 0.220 |
Why?
|
| Systems Analysis | 2 | 2021 | 16 | 0.220 |
Why?
|
| Self-Assessment | 1 | 2005 | 45 | 0.220 |
Why?
|
| Child, Preschool | 4 | 2021 | 3832 | 0.220 |
Why?
|
| Interviews as Topic | 6 | 2016 | 364 | 0.220 |
Why?
|
| Oregon | 2 | 2022 | 23 | 0.220 |
Why?
|
| Community Networks | 2 | 2021 | 32 | 0.210 |
Why?
|
| Tissue and Organ Procurement | 2 | 2020 | 388 | 0.210 |
Why?
|
| Loneliness | 1 | 2024 | 27 | 0.210 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2004 | 24 | 0.210 |
Why?
|
| Texas | 1 | 2024 | 131 | 0.200 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 2718 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 715 | 0.200 |
Why?
|
| Health Personnel | 2 | 2019 | 234 | 0.200 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 889 | 0.200 |
Why?
|
| Fractures, Bone | 1 | 2025 | 155 | 0.200 |
Why?
|
| Needs Assessment | 1 | 2024 | 172 | 0.190 |
Why?
|
| Biological Transport | 1 | 2024 | 399 | 0.190 |
Why?
|
| Drug Utilization | 3 | 2016 | 64 | 0.190 |
Why?
|
| Cholesterol | 3 | 2019 | 364 | 0.190 |
Why?
|
| Tool Use Behavior | 1 | 2023 | 14 | 0.190 |
Why?
|
| Activities of Daily Living | 4 | 2017 | 210 | 0.190 |
Why?
|
| Rural Population | 1 | 2024 | 171 | 0.190 |
Why?
|
| Patient Participation | 2 | 2016 | 230 | 0.190 |
Why?
|
| Washington | 1 | 2022 | 49 | 0.190 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.190 |
Why?
|
| New York | 1 | 2022 | 78 | 0.190 |
Why?
|
| Patient Care Team | 2 | 2010 | 298 | 0.180 |
Why?
|
| Cystitis | 1 | 2002 | 12 | 0.180 |
Why?
|
| Diabetic Neuropathies | 2 | 2016 | 42 | 0.180 |
Why?
|
| Waiting Lists | 2 | 2020 | 211 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2016 | 262 | 0.180 |
Why?
|
| Awards and Prizes | 1 | 2022 | 37 | 0.180 |
Why?
|
| Health Information Exchange | 1 | 2021 | 12 | 0.180 |
Why?
|
| Medical Informatics | 1 | 2022 | 49 | 0.180 |
Why?
|
| Diabetic Nephropathies | 2 | 2016 | 89 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 181 | 0.180 |
Why?
|
| Accelerometry | 2 | 2021 | 48 | 0.170 |
Why?
|
| Postural Balance | 1 | 2021 | 53 | 0.170 |
Why?
|
| Hyperglycemia | 5 | 2014 | 181 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2023 | 4565 | 0.170 |
Why?
|
| Communication | 2 | 2016 | 435 | 0.170 |
Why?
|
| Medical Overuse | 2 | 2018 | 30 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2002 | 85 | 0.170 |
Why?
|
| Cultural Competency | 1 | 2021 | 22 | 0.170 |
Why?
|
| Walking | 1 | 2021 | 104 | 0.160 |
Why?
|
| Fungemia | 1 | 2020 | 15 | 0.160 |
Why?
|
| Liver Transplantation | 1 | 2007 | 1194 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2002 | 195 | 0.160 |
Why?
|
| Mesalamine | 1 | 2021 | 88 | 0.160 |
Why?
|
| Anticholesteremic Agents | 1 | 2001 | 154 | 0.160 |
Why?
|
| Body Temperature | 1 | 2020 | 131 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2016 | 917 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2020 | 2482 | 0.160 |
Why?
|
| Poverty Areas | 1 | 2020 | 37 | 0.160 |
Why?
|
| Diabetic Angiopathies | 2 | 2017 | 37 | 0.160 |
Why?
|
| Health Care Surveys | 5 | 2019 | 286 | 0.150 |
Why?
|
| Bacteremia | 1 | 2020 | 108 | 0.150 |
Why?
|
| Piperidines | 1 | 2021 | 165 | 0.150 |
Why?
|
| Fever | 1 | 2020 | 122 | 0.150 |
Why?
|
| State Health Plans | 1 | 2019 | 13 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 62 | 0.150 |
Why?
|
| Phenotype | 3 | 2021 | 2543 | 0.150 |
Why?
|
| Confidence Intervals | 2 | 2009 | 219 | 0.150 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 80 | 0.150 |
Why?
|
| Withholding Treatment | 1 | 2019 | 121 | 0.140 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 497 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 249 | 0.140 |
Why?
|
| Insulin, Isophane | 1 | 2018 | 2 | 0.140 |
Why?
|
| Insulin Detemir | 1 | 2018 | 3 | 0.140 |
Why?
|
| Early Medical Intervention | 1 | 2018 | 19 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 1923 | 0.140 |
Why?
|
| Insulin Glargine | 1 | 2018 | 12 | 0.140 |
Why?
|
| Endometrial Neoplasms | 1 | 2021 | 227 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2021 | 384 | 0.140 |
Why?
|
| United Kingdom | 2 | 2024 | 190 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 353 | 0.140 |
Why?
|
| Blood Specimen Collection | 2 | 2014 | 28 | 0.130 |
Why?
|
| Sex Factors | 3 | 2018 | 1104 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 990 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2020 | 483 | 0.130 |
Why?
|
| Cost Savings | 1 | 2017 | 68 | 0.130 |
Why?
|
| Models, Statistical | 3 | 2020 | 585 | 0.130 |
Why?
|
| Health Promotion | 1 | 2019 | 171 | 0.130 |
Why?
|
| Medically Uninsured | 2 | 2014 | 67 | 0.130 |
Why?
|
| Machine Learning | 1 | 2020 | 341 | 0.130 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 233 | 0.130 |
Why?
|
| Gangrene | 1 | 2016 | 6 | 0.130 |
Why?
|
| Veterans Health | 1 | 2016 | 19 | 0.130 |
Why?
|
| Prognosis | 4 | 2020 | 3913 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 603 | 0.120 |
Why?
|
| Osteomyelitis | 1 | 2016 | 56 | 0.120 |
Why?
|
| Perception | 2 | 2008 | 179 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2019 | 269 | 0.120 |
Why?
|
| Glycemic Index | 1 | 2016 | 10 | 0.120 |
Why?
|
| Motivation | 4 | 2021 | 310 | 0.120 |
Why?
|
| Coronary Disease | 1 | 2017 | 223 | 0.120 |
Why?
|
| Protein Precursors | 2 | 2013 | 133 | 0.120 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 59 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 875 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 513 | 0.120 |
Why?
|
| Drug Utilization Review | 1 | 2015 | 12 | 0.120 |
Why?
|
| Organizational Culture | 1 | 2016 | 33 | 0.120 |
Why?
|
| Motor Activity | 1 | 2018 | 323 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 190 | 0.110 |
Why?
|
| Long-Term Care | 1 | 2016 | 63 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 49 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 163 | 0.110 |
Why?
|
| Philippines | 1 | 2015 | 22 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 55 | 0.110 |
Why?
|
| Anthropometry | 1 | 2014 | 75 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2017 | 256 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1449 | 0.110 |
Why?
|
| Pregnancy | 1 | 2022 | 3148 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 228 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2014 | 109 | 0.100 |
Why?
|
| Carrier State | 1 | 2013 | 40 | 0.100 |
Why?
|
| Bacteriological Techniques | 1 | 2013 | 38 | 0.100 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 800 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2013 | 30 | 0.100 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2025 | 59 | 0.100 |
Why?
|
| Calcitonin | 1 | 2013 | 40 | 0.100 |
Why?
|
| Patient Access to Records | 1 | 2013 | 2 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 80 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 246 | 0.100 |
Why?
|
| Heart Failure | 2 | 2020 | 1388 | 0.100 |
Why?
|
| Intention | 1 | 2013 | 52 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 85 | 0.090 |
Why?
|
| Risk | 4 | 2016 | 657 | 0.090 |
Why?
|
| Demography | 1 | 2013 | 190 | 0.090 |
Why?
|
| Models, Economic | 2 | 2024 | 62 | 0.090 |
Why?
|
| Survival Rate | 2 | 2014 | 1950 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 356 | 0.090 |
Why?
|
| Remission Induction | 1 | 2014 | 738 | 0.090 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 11 | 0.090 |
Why?
|
| Brain | 2 | 2018 | 2375 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2025 | 580 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 414 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 281 | 0.090 |
Why?
|
| Neoplasms | 2 | 2017 | 3171 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 69 | 0.090 |
Why?
|
| Career Choice | 1 | 2013 | 155 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2011 | 101 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2544 | 0.080 |
Why?
|
| Sodium | 2 | 2022 | 329 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 286 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2019 | 1525 | 0.080 |
Why?
|
| Mental Health | 1 | 2012 | 189 | 0.080 |
Why?
|
| Medical Informatics Applications | 1 | 2010 | 7 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 2018 | 0.080 |
Why?
|
| Cost Sharing | 1 | 2010 | 20 | 0.080 |
Why?
|
| Cost Control | 1 | 2010 | 43 | 0.080 |
Why?
|
| Massachusetts | 2 | 2014 | 36 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 167 | 0.080 |
Why?
|
| Osteosarcoma | 1 | 2011 | 158 | 0.080 |
Why?
|
| Primary Prevention | 1 | 2010 | 86 | 0.080 |
Why?
|
| Budgets | 1 | 2009 | 10 | 0.080 |
Why?
|
| Government Programs | 1 | 2009 | 8 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2010 | 175 | 0.080 |
Why?
|
| Prejudice | 1 | 2009 | 49 | 0.070 |
Why?
|
| Triglycerides | 2 | 2017 | 231 | 0.070 |
Why?
|
| Glucose | 2 | 2022 | 692 | 0.070 |
Why?
|
| Endosonography | 1 | 2009 | 100 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 313 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 559 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2009 | 150 | 0.070 |
Why?
|
| Social Identification | 1 | 2008 | 27 | 0.070 |
Why?
|
| Personnel Management | 1 | 2008 | 7 | 0.070 |
Why?
|
| Interview, Psychological | 1 | 2008 | 69 | 0.070 |
Why?
|
| Sample Size | 1 | 2008 | 128 | 0.070 |
Why?
|
| Los Angeles | 1 | 2007 | 28 | 0.070 |
Why?
|
| Cost Allocation | 1 | 2007 | 5 | 0.070 |
Why?
|
| Parents | 1 | 2010 | 292 | 0.070 |
Why?
|
| Midwestern United States | 1 | 2007 | 90 | 0.070 |
Why?
|
| Specialization | 2 | 2008 | 67 | 0.070 |
Why?
|
| Sexual Behavior | 1 | 2010 | 328 | 0.070 |
Why?
|
| Health Behavior | 2 | 2008 | 182 | 0.070 |
Why?
|
| Poverty | 2 | 2019 | 193 | 0.070 |
Why?
|
| Peer Group | 1 | 2008 | 92 | 0.070 |
Why?
|
| Reimbursement, Incentive | 1 | 2007 | 36 | 0.070 |
Why?
|
| Policy Making | 1 | 2007 | 61 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2008 | 238 | 0.060 |
Why?
|
| Medicine | 2 | 2008 | 95 | 0.060 |
Why?
|
| Cultural Diversity | 1 | 2007 | 63 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 429 | 0.060 |
Why?
|
| Leadership | 1 | 2008 | 149 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1933 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2007 | 176 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2005 | 19 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 1002 | 0.060 |
Why?
|
| Life Change Events | 1 | 2005 | 46 | 0.050 |
Why?
|
| Resource Allocation | 2 | 2019 | 64 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 1054 | 0.050 |
Why?
|
| Masculinity | 1 | 2024 | 17 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 13 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 56 | 0.050 |
Why?
|
| Calibration | 1 | 2024 | 107 | 0.050 |
Why?
|
| Illinois | 1 | 2006 | 520 | 0.050 |
Why?
|
| Self-Management | 1 | 2024 | 44 | 0.050 |
Why?
|
| Synaptic Membranes | 1 | 2004 | 13 | 0.050 |
Why?
|
| Niemann-Pick Diseases | 1 | 2004 | 6 | 0.050 |
Why?
|
| Friends | 1 | 2023 | 20 | 0.050 |
Why?
|
| Family Practice | 1 | 2004 | 73 | 0.050 |
Why?
|
| Cognition | 2 | 2018 | 627 | 0.050 |
Why?
|
| Health Resources | 1 | 2004 | 81 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 6 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 150 | 0.050 |
Why?
|
| Urinalysis | 1 | 2002 | 34 | 0.040 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2011 | 5 | 0.040 |
Why?
|
| Decision Trees | 1 | 2021 | 64 | 0.040 |
Why?
|
| Exercise Test | 1 | 2021 | 152 | 0.040 |
Why?
|
| Vulnerable Populations | 2 | 2014 | 91 | 0.040 |
Why?
|
| Jurisprudence | 1 | 2021 | 24 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 397 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 64 | 0.040 |
Why?
|
| Equipment Design | 1 | 2012 | 416 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 501 | 0.040 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 97 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 85 | 0.040 |
Why?
|
| Blood Culture | 1 | 2020 | 13 | 0.040 |
Why?
|
| Antipyretics | 1 | 2020 | 2 | 0.040 |
Why?
|
| Health Education | 1 | 2011 | 105 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 660 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 32 | 0.040 |
Why?
|
| Troponin | 1 | 2020 | 26 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 133 | 0.040 |
Why?
|
| Infliximab | 1 | 2021 | 162 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 884 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 104 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 828 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 322 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 38 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 88 | 0.040 |
Why?
|
| Creatinine | 1 | 2020 | 293 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 620 | 0.040 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 92 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 451 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2021 | 479 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1918 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 28 | 0.040 |
Why?
|
| Population Health | 1 | 2019 | 33 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 759 | 0.040 |
Why?
|
| Age Distribution | 2 | 2012 | 206 | 0.040 |
Why?
|
| Systole | 1 | 2018 | 83 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2368 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2018 | 118 | 0.030 |
Why?
|
| Glycoproteins | 2 | 2013 | 217 | 0.030 |
Why?
|
| Biological Products | 1 | 2021 | 178 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 136 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 961 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 361 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 217 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2017 | 109 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 12 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 306 | 0.030 |
Why?
|
| Diet Therapy | 1 | 2016 | 19 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2016 | 23 | 0.030 |
Why?
|
| Microvessels | 1 | 2016 | 68 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 87 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 543 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 119 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 156 | 0.030 |
Why?
|
| Medicare Part A | 1 | 2015 | 3 | 0.030 |
Why?
|
| Medicare Part B | 1 | 2015 | 4 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 183 | 0.030 |
Why?
|
| Neurons | 1 | 2004 | 1575 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 47 | 0.030 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2014 | 2 | 0.030 |
Why?
|
| Idaho | 1 | 2014 | 9 | 0.030 |
Why?
|
| Urine Specimen Collection | 1 | 2014 | 8 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 348 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 105 | 0.030 |
Why?
|
| Saliva | 1 | 2014 | 124 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1993 | 64 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 43 | 0.030 |
Why?
|
| Indians, North American | 1 | 2013 | 48 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 1866 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 3158 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2013 | 39 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1993 | 128 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2014 | 295 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2013 | 59 | 0.020 |
Why?
|
| Personnel Turnover | 1 | 2013 | 11 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2013 | 47 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 28 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 110 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 140 | 0.020 |
Why?
|
| Infection Control | 1 | 2013 | 131 | 0.020 |
Why?
|
| Cross Infection | 1 | 2013 | 155 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 174 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 503 | 0.020 |
Why?
|
| Mice | 3 | 2011 | 12233 | 0.020 |
Why?
|
| Proxy | 1 | 2011 | 27 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2011 | 68 | 0.020 |
Why?
|
| Algorithms | 2 | 2011 | 1954 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 876 | 0.020 |
Why?
|
| Holistic Health | 1 | 2010 | 9 | 0.020 |
Why?
|
| Self Report | 1 | 2012 | 329 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 254 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 523 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 824 | 0.020 |
Why?
|
| Sepsis | 1 | 2013 | 388 | 0.020 |
Why?
|
| Time Management | 1 | 2008 | 6 | 0.020 |
Why?
|
| Chronic Pain | 1 | 2011 | 187 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 131 | 0.020 |
Why?
|
| Employee Incentive Plans | 1 | 2008 | 4 | 0.020 |
Why?
|
| Personnel Loyalty | 1 | 2008 | 4 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 449 | 0.020 |
Why?
|
| Professional Autonomy | 1 | 2008 | 38 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1103 | 0.020 |
Why?
|
| Staff Development | 1 | 2008 | 26 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2008 | 164 | 0.020 |
Why?
|
| Rats | 1 | 1993 | 4042 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 804 | 0.020 |
Why?
|
| Workload | 1 | 2008 | 126 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 234 | 0.020 |
Why?
|
| Retreatment | 1 | 2006 | 104 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3479 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2006 | 78 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 91 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2008 | 238 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 690 | 0.010 |
Why?
|
| Social Behavior | 1 | 2008 | 307 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1516 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1735 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 2756 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1719 | 0.010 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 82 | 0.010 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2004 | 7 | 0.010 |
Why?
|
| Guanylate Kinases | 1 | 2004 | 12 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 137 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2004 | 70 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 219 | 0.010 |
Why?
|
| Cytosol | 1 | 2004 | 192 | 0.010 |
Why?
|
| Astrocytes | 1 | 2004 | 137 | 0.010 |
Why?
|
| Dendrites | 1 | 2004 | 97 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 392 | 0.010 |
Why?
|
| Animals | 3 | 2011 | 28041 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 752 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1790 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2828 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1260 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 3430 | 0.010 |
Why?
|
| Gene Conversion | 1 | 1993 | 23 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 119 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1993 | 157 | 0.010 |
Why?
|
| Gene Library | 1 | 1993 | 124 | 0.010 |
Why?
|
| Codon | 1 | 1993 | 116 | 0.010 |
Why?
|
| DNA Primers | 1 | 1993 | 528 | 0.010 |
Why?
|
| Dogs | 1 | 1993 | 634 | 0.010 |
Why?
|
| Primates | 1 | 1993 | 157 | 0.010 |
Why?
|
| Swine | 1 | 1993 | 587 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 890 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 1102 | 0.010 |
Why?
|
| Skin | 1 | 1993 | 576 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 2209 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 2889 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 1260 | 0.000 |
Why?
|